Oricell Therapeutics Co., Ltd, a leading biopharmaceutical company based in China, has announced that it has received fast-track designation from the U.S. Food and Drug Administration (FDA) for its innovative therapy, OriCAR-017. This chimeric antigen receptor (CAR)-T cell therapy is targeted at GPRC5D, aiming to treat recurrent refractory multiple myeloma (R/R MM).
GPRC5D, recognized for its high expression in multiple myeloma cells and lower prevalence in normal tissues, presents a promising therapeutic target for this form of cancer. OriCAR-017 is a pioneering treatment, marking China’s first and the world’s second CAR-T therapy of its kind to reach the clinical stage. The therapy is lauded for its significant differentiated advantages, including rapid development, efficacy, and safety profiles.- Flcube.com
